Twenty-two cases of pulmonary plasmacytoma have been reported in the literature and verified by immunohistochemistry or other diagnostic tests. The treatment for this rare tumor has included various combinations of surgical resection, chemotherapy, and radiation therapy. We report a case of a middle-age man who underwent endoscopic debulking followed by laser ablation for a pulmonary plasmacytoma, which showed a prominent endobronchial location with clinical and histopathologic verification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0003-4975(03)01474-7 | DOI Listing |
Int J Surg Case Rep
January 2025
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address:
Introduction And Importance: Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm, constituting around 3 % of plasma cell malignancies. SEP typically presents as a single tumor, either in bone or soft tissue, without systemic disease, and is often misdiagnosed due to its nonspecific symptoms. Diagnosis requires biopsy and extensive imaging studies to exclude multiple myeloma and other malignancies.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Respiratory and Critical Care Medicine, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Cancer Rep (Hoboken)
November 2024
Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.
Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.
Cureus
October 2024
Orthopedic Surgery, Kindai University Hospital, Osakasayama, JPN.
Background: We conduct a retrospective analysis of patients with pathological fractures resulting from upper extremity malignancies, focusing on the evaluation of treatment strategies employed.
Materials And Methods: We retrospectively studied 10 patients with metastatic bone tumors of the upper extremities. The study variables included tumor site, primary pathology, duration from the first diagnosis of the primary lesion to the occurrence of the pathological fracture, use of bone-modifying drugs, surgical technique, adjuvant therapy, postoperative functional assessment, Katagiri's score, American Society of Anesthesiologists physical status (ASA-PS), outcome, and correlations between the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and Musculoskeletal Tumor Society (MSTS) score.
Diagnostics (Basel)
August 2024
Department of Radiology, General University of Patras, 61000 Patras, Greece.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!